A simple 60/40 portfolio model would’ve easily beaten the returns that hedge-fund investors enjoyed, according to an estimate of their performance. Barclays estimated the weighted average ...

We recently published a list of 12 Stocks That Could Split in the Near Future. In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against other stocks that could ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

However, while there are many unknowns right now, there are plenty of reasons to be optimistic about Lilly. Sales for Mounjaro and Zepbound should continue to grow. Lilly could launch another ...

it's in a great position to grow its sales and profits for years to come. In Eli Lilly's most recent quarter, which ended on Sept. 30, 2024, it grew its sales by 20% to $11.4 billion. It also had ...